-
effectivehealthcare.ahrq.gov/products/ischemic-stroke-treatment/research-protocol
February 19, 2010 - with events in large cerebral vessels having particularly high clot burden which may not adequately respond
-
effectivehealthcare.ahrq.gov/products/distributed-network-blueprint/research
June 23, 2010 - procedure, as this would facilitate development of network queries and minimize the effort needed to respond
-
effectivehealthcare.ahrq.gov/sites/default/files/nt_docs/topic-brief-updating-pharmacotherapy.pdf
September 30, 2022 - Patients who do not respond to first line treatment are recommended
second-line pharmacotherapies using … We considered whether or not the clinical, consumer, or
policymaking context had the potential to respond
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/ischemic-stroke-treatment_executive.pdf
January 01, 2011 - involved
patients with large vessel occlusions, high baseline
NIHSS scores, and those either unlikely to respond
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/ischemic-stroke-treatment_research-protocol.pdf
February 19, 2010 - with events in large cerebral vessels having particularly
high clot burden which may not adequately respond
-
effectivehealthcare.ahrq.gov/sites/default/files/prehospital-airway-management-draft-appendix-e.xlsx
July 01, 2018 - Characteristics
Author, Year Year KQ 1
BVM vs SGA KQ 2
BVM vs ETI KQ 3
SGA vs ETI KQ4
Variations of Single Airway Study Design Country Setting # of Agencies/
Institutions Registry Y/N
Name of Registry Study Time Period Age Groups Emergency Type Prehospital Provider Study level provider Group Mode of Transport Eligibil…
-
effectivehealthcare.ahrq.gov/products/dietary-supplements/research-protocol
December 21, 2010 - Current Page Topic Timeline Apr. 1, 2009 Topic Suggestion Dec. 21, 2010 Research Protocol Apr. 30, 2012 Systematic Review Jul. 3, 2013 Surveillance Report Comparative Effectiveness of Dietary Supplement Versus No Dietary Supplement Use in Adults Taking Cardiovascular Drugs
Research Protocol Archived December 21, 2…
-
effectivehealthcare.ahrq.gov/products/cancer-anemia-update/research-protocol
June 16, 2010 - consider the dose density/intensity of the ESA, particularly in those recipients who do not initially respond
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-disease-medicine_surveillance.pdf
October 01, 2012 - CER # 37:
Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and
Treatment
Original release date:
January 2012
Surveillance Report:
October 2012
Key Findings:
- The conclusions for KQ2 (harms of screening) and KQ4
(harms of monitoring), KQ6 (harms of treatment) are still
considered valid
- T…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/ced-topic-refinement.pdf
November 01, 2022 - Topic Refinement
Analysis of Requirements for Coverage With Evidence
Development (CED) – Topic Refinement
Prepared for:
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
5600 Fishers Lane
Rockville, MD 20857
www.ahrq.gov
and
Centers for Medicare and Medicaid Services
7…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/people-with-disabilities-draft-report-app-e-f.xlsx
January 01, 2022 - Geographic location: NR
Note: baseline characteristics include PwD (n=18) and their caregiver if PwD cannot respond
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/venous-ulcers-treatment_disposition-comments.pdf
January 27, 2014 - Disposition of Comments Report for Chronic Venous Ulcers: A Comparative Effectiveness Review of Treatment Modalities
Comparative Effectiveness Review Disposition of Comments Report
Research Review Title: Chronic Venous Ulcers: A Comparative Effectiveness Review of
Treatment Modalities
Draft review av…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/epilepsy-medicine_surveillance.pdf
August 01, 2012 - CER #40:
Effectiveness and Safety of Antiepileptic Medications
in Patients with Epilepsy
Original release date:
December, 2011
Surveillance Report:
November, 2012
Key Findings:
- Contacted experts thought many conclusions for KQ1 to 4
do not make sufficiently clear that they are based on
insufficien…
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/epilepsy-medicine_surveillance.pdf
August 01, 2012 - CER #40:
Effectiveness and Safety of Antiepileptic Medications
in Patients with Epilepsy
Original release date:
December, 2011
Surveillance Report:
November, 2012
Key Findings:
- Contacted experts thought many conclusions for KQ1 to 4
do not make sufficiently clear that they are based on
insufficien…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-disease-ace-inhibitor-arb_surveillance.pdf
July 06, 2015 - Untitled
AHRQ Comparative Effectiveness Review
Surveillance Program
CER #18: Comparative Effectiveness of Angiotensin
Converting Enzyme Inhibitors or An…
-
effectivehealthcare.ahrq.gov/sites/default/files/clinical-pathway-methods-report-appendix-k.pdf
February 01, 2018 - mg 4 times daily for 10 days
(Conditional recommendation, moderate-quality evidence)
• Failure to respond … for
Health and Care
Excellence [NICE]
20149
In patients with recurrent CDI who have failed to respond
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/migraine-emergency_executive.pdf
November 01, 2012 - It is unknown whether males respond
differently than females to the interventions included in
this … • Future RCTs should investigate important
subpopulations who may differentially respond to
migraine
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-211-rheumatoid-arthritis-disposition-comments.pdf
December 20, 2018 - Studies confirm that the
percent of inadequate responders to MTX who respond to
subsequent biologic
-
effectivehealthcare.ahrq.gov/system/files/docs/topic-brief-antenatal-care.pdf
April 01, 2021 - We considered whether or not the clinical, consumer, or
policymaking context had the potential to respond
-
effectivehealthcare.ahrq.gov/system/files/docs/na_liver_disease_topic_brief_topic_brief.pdf
October 30, 2020 - We considered whether or not the clinical, consumer, or
policymaking context had the potential to respond